Drisapersen Treatment For Duchenne Muscular Dystrophy: Results Of A 96-Week Follow-Up Of An Open-Label Extension Study Following Two Placebo-Controlled Trials

The Emerging Science abstracts were presented at the 2014 AAN Annual Meeting. Abstracts qualify for Emerging Science presentations by having key aspects of research conducted after the October 28th abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication. The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting; 10 abstracts were accepted for dual presentation and 14 were accepted as poster presentations. The last 2 abstracts were presented at the Clinical Trials Plenary Session.